# **Supplementary Material**

Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in triple-negative breast cancer

Yongqi Zhen<sup>a, b</sup>, Rongyan Zhao<sup>a</sup>, Minjuan Wang<sup>a</sup>, Xing Jiang<sup>a</sup>, Feng Gao<sup>a</sup>, Leilei Fu<sup>a\*</sup>, Lan Zhang<sup>a\*</sup>, Xian-Li Zhou<sup>a, b\*</sup>

<sup>a</sup>School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, P.R. China.

<sup>b</sup>Key Laboratory of Advanced Technologies of Materials, Ministry of Education, Southwest Jiaotong University, Chengdu, P.R. China.

\*Correspondence: Dr. Leilei, Fu, E-mail: leilei\_fu@163.com; Dr. Lan, Zhang, E-mail: zhanglanx\_9@126.com; Prof. Xian-Li, Zhou, E-mail: zhouxl@swjtu.edu.cn. Postal address: School of Life Science and Engineering, Southwest Jiaotong University, NO.111, North Second Ring Road, Chengdu 610031, Sichuan, P.R. China.



Figure S1. Antitumor effect of flubendazole. (A-C) The cell viability of concentration-dependent and time-dependent treated with flubendazole in various tumor lines. Cell viabilities were

measured by MTT assay, and the  $\mathrm{IC}_{50}$  values were calculated by Prism 7.0. Data are expressed as

mean  $\pm$  SEM. All data were representative of at least three independent experiments.



**Figure S2.** Cell viability of flubendazole on normal breast cells and TNBC cells. (A) The cell viability of concentration-dependent treated with flubendazole for 24 h. Cell viabilities were measured by MTT assay. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. \*\*, P < 0.01, \*\*\*, ###, P < 0.001. Statistical significance compared with respective control groups.



**Figure S3.** Immunohistochemistry from tumor sections or lung tissue in nude mice. (A-H) Representative images of Ki67, LC3, p62, E-cadherin, MPP-2, EVA1A, HAP1 and HIF1 $\alpha$  in nude mice tumor sections or lung tissues and their respective negative controls, which used as the indication of antibody specificity.



Figure S4. Flubendazole inhibits TNBC *in vivo*. (A) Body weight change of mice in different group, compared with control group. (B) Representative H&E staining in heart, liver, spleen, lung, kidney sections. Scale bar, 40  $\mu$ m. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments.



**Figure S5.** Flubendazole induces autophagy *in vivo*. (A-B) The expression of p62 and LC3 in representative tumor sections of nude mice from control and median dose (20 mg/Kg). Representative images and quantitative analysis of the percentage of positive ratios were shown. Scale bar, 40  $\mu$ m. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. \*, *P* < 0.05, \*\*, *P* < 0.01, \*\*\*, *P* < 0.001. Statistical significance compared with respective control groups.



Figure S6. MDA-MB-231 cells were transfected with control or ATG5 siRNA. Then, the expression levels of ATG5 was determined by western blot analysis.  $\beta$ -Actin was measured as the loading control.



**Figure S7.** Flubendazole downregulates the expression of HIF1 $\alpha$  *in vitro*. Immunofluorescence analysis of HIF1 $\alpha$  in MDA-MB-231 and MDA-MB-468 cells treated with or without flubendazole (0.5  $\mu$ M) for 24 h. Scale bar, 20  $\mu$ m. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. \*, *P* < 0.05, \*\*, *P* < 0.01, \*\*\*, *P* < 0.001. Statistical significance compared with respective control groups.



**Figure S8.** Flubendazole regulates the expression of HAP1, EVA1A and HIF1*a in vivo*. (A-C) The expression of HAP1, EVA1A and HIF1*a* in representative lung sections of nude mice from vehicle and median dose (20 mg/Kg). Representative images and quantitative analysis of the percentage of positive ratios were shown. Scale bar, 40 µm. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. \*, *P* < 0.05, \*\*, *P* < 0.01, \*\*\*\*, *P* < 0.001. Statistical significance compared with respective control groups.



**Figure S9.** Flubendazole elicits anti-migration potential via targeting EVA1A *in vitro*. (A) The MDA-MB-231 cells were transfected with control or EVA1A siRNA, followed by treatment with or without flubendazole (0.5  $\mu$ M) for 24 h. Transwell assay was used to measure migration capabilities of cells. Representative images and statistics were shown. Scale bar, 100  $\mu$ m. (B-C) The MDA-MB-231 cells were transfected with control or EVA1A siRNA, followed by treatment with or without flubendazole (0.5  $\mu$ M) for 24 h. The expression of MMP-2 and E-cadherin were

analyzed by immunofluorescence. Scale bar, 20  $\mu$ m. Data are expressed as mean  $\pm$  SEM. All data were representative of at least three independent experiments. \*, *P* < 0.05, \*\*, *P* < 0.01, \*\*\*, *P* < 0.001. Statistical significance compared with respective control groups.

# Supplementary Table 2. List of siRNA or cDNA sequences

Gene name	siRNA sense sequences (5'-3')
si-EVA1A	GAGCCTGAATCGCTACTATTA
si-Control	TTCTCCGAACGTGTCACGT

<b>Recombinant DNA</b>	DNA sense sequences
C-terminal Flag-tagged EVA1A <sup>WT</sup>	ATGAGGCTGCCCCTCAGCCACAGCCCAGAGCACGTGGAGATGGCTTTG
	CTCAGCAACATCCTAGCGGCCTATTCCTTTGTCTCAGAAAATCCTGAGC
	GAGCAGCTCTGTACTTTGTTTCTGGCGTGTGCATCGGGCTGGTGCTGAC
	CCTGGCTGCTCTGGTGATAAGGATCTCTTGCCACAGACTGCAGGCGG
	CGTCCCGGGAAGAAGTTCCTGCAGGACAGAGAGAGAGCAGCAGCAGCAAG
	CAGCGACAGCGAGGATGGCAGTGAGGACACCGTGTCCGATCTCCCGT
	GCGGAGACACCGCCGCTTCGAGAGGACTTTGAACAAGAATGTGTTCAC
	CTCTGCGGAGGAGCTGGAGCGCGCGCCCAGCGGCTGGAGGAGCGCGAGC
	GCATCATCAGGGAGATCTGGATGAATGGCCAGCCTGAGGTGCCCGGGA
	CCAGGAGCCTGAATCGCTACTATTAGGACTACAAGGATGACGATGACAA
	GGATTACAAAGACGACGATAAGGACTATAAGGATGATGACGACAAA
	ATGAGGCTGCCCCTCAGCCACAGCCCAGAGCACGTGGAGATGGCTTTG
	CTCAGCAACATCCTAGCGGCCTATTCCTTTGTCTCAGAAAATCCTGAGC
	GAGCAGCTCTGTACTTTGTTTCTGGCGTGTGCATCGGGCTGGTGCTGAC
	CCTGGCTGCTCTGGTGATAAGGATCTCTTGCCACACAGACTGCAGGCGG
	CGTCCCGGGAAGAAGTTCCTGCAGGACAGAGAGAGAGCAGCAGCGACAG
C-terminal Flag-tagged	CAGCGACAGCGAGGATGGCAGTGAGGACACCGTGTCCGATCTCCCGT
EVAIA	GCGGAGACACCGCCGCTTCGAGAGGACTTTGAACAAGGCTGTGTTCAC
	CTCTGCGGAGGAGCTGGAGCGCGCGCCCAGCGGCTGGAGGAGCGCGAGC
	GCATCATCAGGGAGATCTGGATGAATGGCCAGCCTGAGGTGCCCGGGA
	CCAGGAGCCTGAATCGCTACTATTAGGACTACAAGGATGACGATGACAA
	GGATTACAAAGACGACGATAAGGACTATAAGGATGATGACGACAAA
	ATGAGGCTGCCCCTCAGCCACAGCCCAGAGCACGTGGAGATGGCTTTG
	CTCAGCAACATCCTAGCGGCCTATTCCTTTGTCTCAGAAAATCCTGAGC
C-terminal Flag-tagged EVA1A <sup>W135A</sup>	GAGCAGCTCTGTACTTTGTTTCTGGCGTGTGCATCGGGCTGGTGCTGAC
	CCTGGCTGCTCTGGTGATAAGGATCTCTTGCCACACAGACTGCAGGCGG
	CGTCCCGGGAAGAAGTTCCTGCAGGACAGAGAGAGAGCAGCAGCGACAG
	CAGCGACAGCGAGGATGGCAGTGAGGACACCGTGTCCGATCTCCCGT
	GCGGAGACACCGCCGCTTCGAGAGGACTTTGAACAAGAATGTGTTCAC
	CTCTGCGGAGGAGCTGGAGCGCGCGCCCAGCGGCTGGAGGAGCGCGAGC
	GCATCATCAGGGAGATCGCGATGAATGGCCAGCCTGAGGTGCCCGGGA
	CCAGGAGCCTGAATCGCTACTATTAGGACTACAAGGATGACGATGACAA
	GGATTACAAAGACGACGATAAGGACTATAAGGATGATGACGACAAA
C-terminal Flag-tagged EVA1A <sup>T113A</sup>	ATGAGGCTGCCCCTCAGCCACAGCCCAGAGCACGTGGAGATGGCTTTG
	CTCAGCAACATCCTAGCGGCCTATTCCTTTGTCTCAGAAAATCCTGAGC
	GAGCAGCTCTGTACTTTGTTTCTGGCGTGTGCATCGGGCTGGTGCTGAC
	CCTGGCTGCTCTGGTGATAAGGATCTCTTGCCACACAGACTGCAGGCGG
	CGTCCCGGGAAGAAGTTCCTGCAGGACAGAGAGAGAGCAGCAGCGACAG

CAGCGACAGCGAGGATGGCAGTGAGGACACCGTGTCCGATCTCCCGT
GCGGAGACACCGCCGCTTCGAGAGGACTTTGAACAAGAATGTGTTCGC
CTCTGCGGAGGAGCTGGAGCGCGCCCAGCGGCTGGAGGAGCGCGAGC
GCATCATCAGGGAGATCTGGATGAATGGCCAGCCTGAGGTGCCCGGGA
CCAGGAGCCTGAATCGCTACTATTAGGACTACAAGGATGACGATGACAA
GGATTACAAAGACGACGATAAGGACTATAAGGATGATGACGACAAA